Pathologically or histologically confirmed resectable and accompanied by high-risk factors (high-risk factors include: serum CA19-9, CA19-9>1000 U/ml
Conditions
Interventions
experimental group:Irinotecan hydrochloride liposome + oxaliplatin +S-1+Camrelizumab
Sponsors
The first people's Hospital of Yunnan Province
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The patient fully understood this study, voluntarily participated and signed the informed Consent Form (ICF); 2. Age >= 18 years old; 3. Pathologically or histologically confirmed resectable and accompanied by high-risk factors (high-risk factors include: serum CA19-9, CA19-9>1000 U/ml;) Larger primary pancreatic tumors, with the maximum diameter of the primary tumor >3.0cm; The maximum diameter of regional lymph nodes is greater than 1.0 cm. NRS score: 7 to 10 points; Researchers judged patients with pancreatic cancer who had significant weight loss, were on the verge of being resectable, and were in the locally advanced stage. 4. Has not received any form of anti-tumor treatment in the past; 5. According to RECIST1.1/mRECIST standards, the patient has at least one measurable target lesion; 6. Eastern Cancer Collaboration Group (ECOG) Physical Condition Score: 0-2 points; 7. Expected survival time >= 3 months; 8. Absolute neutrophil count (ANC) >= 1.5×10^9/L, platelet count >= 100×10^9/L and hemoglobin >= 90 g/L (no blood transfusion, blood products, use of granulocyte colony-stimulating factor or other hematopoietic stimulating factors for correction within 14 days prior to the laboratory test); 9. Liver and kidney functions: Serum creatinine <= 1.5 times the upper limit of the normal value; AST and ALT <= 2.5 times the upper limit of the normal value (<= 5 times the upper limit of the normal value for patients with liver invasion); Total bilirubin <= 1.5 times the upper limit of the normal value (<= 3 times the upper limit of the normal value for patients with liver invasion);
Exclusion criteria
Exclusion criteria: 1. Any form of anti-tumor treatment, including radiotherapy, chemotherapy, molecular targeted therapy and immunotherapy, has been received within 4 weeks before enrollment; 2. Have hypersensitivity reactions to any research drug or its components; 3. Concurrent severe uncontrolled concurrent infections or other severe uncontrolled concomitant diseases, moderate or severe kidney injury; (Such as advanced infection, uncontrollable hypertension, diabetes, etc.); 4. Heart diseases evaluated by the cardiology department as intolerant to treatment; 5. Active hepatitis B and C infections (positive hepatitis B surface antigen and hepatitis B virus DNA exceeding 1x103 copies /mL; Hepatitis C virus RNA exceeds 1x103 copies /mL; 6. Human Immunodeficiency virus (HIV) infection (HIV antibody positive); 7. Have had or are currently concurrently suffering from other malignant tumors (except for effectively controlled non-melanoma basal cell carcinoma of the skin, carcinoma in situ of the breast/cervix, and other malignant tumors that have been effectively controlled without treatment in the past five years); 8. Pregnant and lactating women and patients of childbearing age who are unwilling to take contraceptive measures; 9. Those with other malignant tumors that require treatment; 10. The researchers determined that patients were not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Surgical resection rate;R0 resection rate; | — |
Countries
China
Contacts
Public ContactJin Yun
The first people's Hospital of Yunnan Province
Outcome results
None listed